You are here

Structural & Congenital Heart Disease


Patients who received a mechanical prosthesis for surgical replacement of aortic or mitral valves derived a significant long-term survival benefit versus those who received a biologic prosthesis, according to a study in the New England Journal of Medicine.

Nearly half of all valve hospitals in the U.S. are misclassified as either low- or high-performing, according to research published in JAMA Cardiology—but that problem might have a simple fix.

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Research examining 278 patients with in-stent restenosis (ISR) found that drug-eluting balloon (DEB) was non-inferior in comparison with drug-eluting stent (DES) in terms of six-month minimal lumen diameter (MLD).

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.


Recent Headlines

Time of year, day of week could influence incidence of MI

New research suggests that certain times of year or days of the week could have an effect on the incidence of myocardial infarction (MI).

FDA, health orgs encourage better ways to test heart drugs in children

In a new health policy statement, the U.S. Food and Drug Administration (FDA) and other major health organizations have called for improvements in the way medications are developed and tested in children with heart disease.

Making the Call for Closure: Heart–Brain Teams Strive to Improve Patient Selection for PFO Closure

Did the patent foramen ovale (PFO) cause the patient’s stroke? This, experts say, is the key question when deciding whether to recommend PFO closure. Heart–brain teams can help with the answer.   

A Practical Guide to Palliative Care for Heart Failure Patients

With a few practical steps, cardiology practices can meet the palliative care needs of heart failure patients.     

Healing hearts, one molecule at a time

We cut a finger and the skin heals. But what if hearts could heal too? Researchers recently found a molecule in newborns that might help, some day. The team at the Weizmann Institute of Science have identified a molecule found in newborns that appears to control the renewal process, assisting regeneration in damaged hearts.

Scientists ID cell that can regenerate heart tissue after MI

Researchers at the Weizmann Institute of Science in Israel have uncovered a molecule found in newborns that aids in regenerating damaged hearts—and are now testing ways that the molecule could treat heart attack victims.

Amgen seeks market approval for Repatha in U.S., Europe

Thousand Oaks, California-based Amgen has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) and a variation of one in Europe seeking approval for Repatha, a PCSK9 inhibitor.

Liver disease more prominent in Fontan surgery patients, research shows

New research from the Children’s Hospital of Philadelphia shows patients who have undergone the Fontan operation as children are at an increased risk for developing progressive liver fibrosis.

Chemotherapy-induced cardiomyopathy hits men harder than women

A small study examining how chemotherapy-induced cardiomyopathy found that men experienced greater side effects, including significantly lower left and right ventricular ejection.

New research clarifies why we think moderate drinking is heart healthy

We’ve all heard that a glass of wine could be good for your heart, but new evidence from research at the University of Victoria in British Columbia, Canada, says otherwise.